HANCOCK DANIEL M 4

4 · Cryoport, Inc. · Filed Oct 22, 2021

Insider Transaction Report

Form 4

Period: 2021-10-20

Cryoport, Inc.CYRX

HANCOCK DANIEL M

Director

Transactions

Exercise/Conversion
Common Stock
[F1]
2021-10-20$14.35/sh+3,783$54,286→ 8,410 total
Sale
Common Stock
[F1][F2]
2021-10-20$75.17/sh−3,783$284,385→ 4,627 total
Exercise/Conversion
Common Stock
[F1]
2021-10-21$14.35/sh+11,217$160,964→ 15,844 total
Sale
Common Stock
[F1][F3]
2021-10-21$75.29/sh−5,900$444,205→ 9,944 total
Sale
Common Stock
[F1][F4]
2021-10-21$76.24/sh−5,317$405,391→ 4,627 total
Exercise/Conversion
Option to purchase common stock
[F1][F5]
2021-10-20−3,783→ 11,217 total
Exercise: $14.35Exp: 2029-05-02→ Common Stock (3,783 underlying)
Exercise/Conversion
Option to purchase common stock
[F1][F5]
2021-10-21−11,217→ 0 total
Exercise: $14.35Exp: 2029-05-02→ Common Stock (11,217 underlying)

Footnotes (5)

[F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 15, 2021.
[F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.90 to $75.40, inclusive. The reporting person undertakes to provide to Cryoport, Inc., any security holder of Cryoport, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F3]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.90 to $75.89, inclusive. The reporting person undertakes to provide to Cryoport, Inc., any security holder of Cryoport, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F4]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.91 to $76.63, inclusive. The reporting person undertakes to provide to Cryoport, Inc., any security holder of Cryoport, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F5]1/12 of these options vested and became exercisable in equal monthly installments on the 2nd of each month for the twelve (12) months beginning on 05/02/2019.

Signature

/s/ Daniel Hancock|2021-10-22

Documents

1 file

4
tm2130870d1_4.xmlPrimary
OWNERSHIP DOCUMENT